-- 据媒体周一报道,荷兰政府宣布了一项价值约10亿欧元(12亿美元)的一系列措施,旨在帮助家庭和企业应对不断上涨的能源成本,同时启动紧急应对计划,以应对日益加剧的全球能源供应中断担忧。 这些措施包括为通勤者、卡车司机和渔民提供临时税收减免,以及提高员工的免税差旅津贴。该方案还为低收入家庭提供定向支持,包括约1.95亿欧元用于补贴能源账单,以及鼓励房主减少能源消耗的激励措施。 尽管受影响行业施加压力,但政府再次拒绝大幅削减燃油税。 此举正值荷兰准备应对中东冲突带来的更多经济影响之际。霍尔木兹海峡是石油和天然气运输的关键通道,其关闭推高了欧洲能源价格,并引发了人们对供应趋紧的担忧。 官员表示,目前没有迫在眉睫的燃料短缺,并指出欧洲的石油、柴油和航空燃油供应足以满足长达一年的需求。然而,当局警告称,他们正在为局势可能恶化做好准备。 这是自2022年俄罗斯入侵乌克兰引发能源危机以来,这项四阶段计划首次启动。 据报道,财政大臣埃尔科·海宁表示,政府正在考虑局势进一步升级的风险,并准备在必要时采取额外措施。 荷兰政府尚未回复的置评请求。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.